21 results
6-K
EX-99.2
MDNAF
Medicenna Therapeutics Corp.
14 Feb 24
Interim condensed consolidated financial statements of
7:30am
toxin, Pseudomonas exotoxin, which effectively arrests protein synthesis leading to cell death. The IL-4 component is engineered and designed … and lung cancer but minimally expressed in healthy tissues. A fusion of MDNA213 with a toxin selectively caused cell death in IL-13Rα2 expressing cancer
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
1 Aug 23
Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
12:01pm
for enhancing immune cell survival and proliferation or inhibiting cell death and therefore improving fitness of cancer fighting immune cells.
TORONTO
6-K
EX-99.2
MDNAF
Medicenna Therapeutics Corp.
28 Jul 23
Interim condensed consolidated financial statements of
8:31am
(pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in the ongoing Phase 1/2 ABILITY Study. Under the terms of the CTCSA, Medicenna
6-K
EX-99.2
dn3v iipr
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
6-K
EX-99.1
bgqzg8apjrodwc
13 Sep 22
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial
4:38pm
6-K
EX-99.1
d3j8453
11 Aug 22
Current report (foreign)
12:53pm
20-F
EX-4.7
8xbcaw00uq1
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-4.1
f9byntj l8uf3s
22 Jun 22
Annual report (foreign)
5:04pm
20-F
44szv gpe17t
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-15.1
va3p079cb3jdxy3a
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-4.6
bx1mf5cdw51rdpskm7
22 Jun 22
Annual report (foreign)
5:04pm
6-K
EX-99.1
nd8hu7j wpdu
22 Jun 22
Current report (foreign)
8:00am
6-K
EX-99.3
6wbfiyqa
22 Jun 22
Current report (foreign)
8:00am
6-K
EX-99.1
oi9vm6f06y
9 Jun 22
Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent
7:39am
6-K
EX-99.1
5j1u89
11 May 22
Current report (foreign)
8:24am
40-F
EX-99.1
9osean
28 May 21
Annual report (Canada)
12:12pm
S-8
EX-4.4
1sbtz
31 Jul 20
Registration of securities for employees
8:43am
S-8
EX-99.1
angifj8cewp7 vkqdn
31 Jul 20
Registration of securities for employees
8:43am